UPDATE: Jefferies Raises PT to $18 on ARIAD Pharmaceuticals; Regulatory Catalysts

Jefferies raises its price target from $17 to $18 on Buy-rated ARIAD Pharmaceuticals ARIA on regulatory catalysts, despite a wider Q loss. Jefferies notes, "Wider 1Q net loss of $56M (vs. our est of $39M) largely due to non-cash charge related to warrant liability revaluation. Despite higher OpEx expected in 2012, cash at end-1Q12 of $288M should be sufficient thru 1H13. With regulatory catalysts within next 12 months (ponatinib NDA filing in 3Q12/potential FDA approval early-2013), we believe ARIA is well positioned for meaningful upside." ARIA closed at $15.91 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetReiterationPre-Market OutlookAnalyst RatingsJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!